SOUTH SAN FRANCISCO, Calif., Feb. 14, 2018 — MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that senior management will participate in a fireside chat at the RBC Capital Marketsâ€™ 2018 Healthcare Conference on Wednesday, February 21, 2018, at 8:30 a.m. ET in New York, NY.
A webcast of the presentation will be available by visiting the Investors section of MyoKardiaâ€™s website at http://investors.myokardia.com. A replay of the webcast will be available on the MyoKardia website for 90 days following the conference.About MyoKardiaMyoKardia is a clinical-stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and rare cardiovascular diseases. MyoKardiaâ€™s initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. MyoKardia has used its precision medicine platform to generate a pipeline of therapeutic programs for the chronic treatment of the two most prevalent forms of heritable cardiomyopathy â€“ hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM). MyoKardiaâ€™s most advanced product candidate is mavacamten (MYK-461), a novel, oral, allosteric modulator of cardiac myosin that has been shown to reduce hypercontractility in early clinical studies and is currently being studied in the Phase 2 PIONEER-HCM clinical trial. MYK-491, MyoKardiaâ€™s second product candidate, is designed to increase the overall extent of the heartâ€™s contraction in DCM patients by increasing cardiac contractility. MyoKardia is currently evaluating MYK-491 in a Phase 1b study in DCM patients. A cornerstone of the MyoKardia platform is the Sarcomeric Human Cardiomyopathy Registry (SHaRe), a multi-center, international repository of clinical and laboratory data on individuals and families with genetic heart disease, which MyoKardia helped form in 2014. MyoKardiaâ€™s mission is to change the world for patients with serious cardiovascular disease through bold and innovative science.ContactsBeth DelGiacco (Investors)
Stern Investor Relations, Inc.
[email protected]Steven Cooper (Media)
Latest posts by Sarah Thompson (see all)
- Oncolytics Biotech(R) Announces Results from Special Meeting of Shareholders - February 23, 2018
- Investor Alert: Kaplan Fox Announces Investigation Of Super Micro Computer, Inc. - February 23, 2018
- Salesforce Grants Equity Awards Under Its Inducement Equity Incentive Plan - February 23, 2018